NCT04218552View on ClinicalTrials.gov

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

February 25, 2021

Study Completion Date

February 25, 2021

Conditions
Hypertension,Essential
Interventions
DRUG

AD209

PO, Once daily(QD), 8weeks

DRUG

Amlodipine low

PO, Once daily(QD), 8weeks

DRUG

Amlodipine high

PO, Once daily(QD), 8weeks

DRUG

Telmisartan

PO, Once daily(QD), 8weeks

Trial Locations (1)

Unknown

Korea University Guro Hospital, Seoul

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT04218552 - Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension | Biotech Hunter | Biotech Hunter